Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)

14 novembre 2026 aggiornato da: Rahel Bachem

STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial

This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Descrizione dettagliata

Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.

STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.

Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.

This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.

The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.

Tipo di studio

Interventistico

Iscrizione (Stimato)

70

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Rahel Bachem, Prof. Dr.
  • Numero di telefono: +41 58 257 35 26
  • Email: rahel.bachem@ost.ch

Luoghi di studio

    • Canton of St. Gallen
      • Sankt Gallen, Canton of St. Gallen, Svizzera, 9001
        • Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
  • Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
  • Sufficient German language proficiency to participate in psychotherapy and complete study assessments
  • Capacity to provide written informed consent

Exclusion Criteria:

  • Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
  • Current prolonged grief disorder meeting ICD-11 diagnostic criteria
  • Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
  • Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
  • Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
  • Acute suicidality requiring immediate crisis intervention
  • Ongoing psychotherapy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: STEP Intervention Group

Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

Altro: Waitlist Control Group

Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adjustment Disorder Symptom Severity at Post-Treatment
Lasso di tempo: Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)

Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores.

Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
Depressive Symptom Severity
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Anxiety Symptom Severity
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Perceived Stress
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Subjective Well-Being
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Experiential Avoidance
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Adjustment Disorder Diagnostic Status
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Treatment Credibility and Expectancy
Lasso di tempo: Immediately after STEP Session 1

Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement.

Immediately after STEP Session 1
Treatment Acceptability and Feasibility
Lasso di tempo: Immediately after completion of the 12-session STEP treatment

Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP.

Immediately after completion of the 12-session STEP treatment
Event-Focused Repetitive Thoughts
Lasso di tempo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

1 marzo 2029

Completamento dello studio (Stimato)

1 maggio 2029

Date di iscrizione allo studio

Primo inviato

14 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STEP_PILOTSTUDY
  • PT0041_222855 (Altro numero di sovvenzione/finanziamento: Swiss National Science Foundation - SNSF)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.

Periodo di condivisione IPD

The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.

Criteri di accesso alla condivisione IPD

The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi